Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C60810
http://purl.obolibrary.org/obo/NCIT_C60810
|
|---|---|
| Preferred Name | Tinzaparin Sodium |
| Definitions |
The sodium salt of a low molecular weight heparin (LMWH), obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa, with antithrombotic properties. Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The sodium salt of a low molecular weight heparin (LMWH), obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa, with antithrombotic properties. Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis. |
|---|---|
| prefLabel | Tinzaparin Sodium
|
| label | Tinzaparin Sodium
|
| PDQ_Closed_Trial_Search_ID | 467737
|
| code | C60810
|
| prefixIRI | NCIT:C60810
|
| in_subset |
See more
See less
|
| Display_Name | Tinzaparin Sodium
|
| Preferred_Name | Tinzaparin Sodium
|
| FDA_UNII_Code | 3S182ET3UA
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | (C14H18NO11)n.2(C12H15NO13S)n.3Na.3O3S
|
| Maps_To | Tinzaparin Sodium
|
| CAS_Registry | 9041-08-1
|
| NCI_Drug_Dictionary_ID | 467737
|
| Legacy Concept Name | Tinzaparin
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| ALT_DEFINITION | A drug that is used with another drug, warfarin, to treat blood clots that form deep in the veins and to prevent new blood clots from forming. It is a type of anticoagulant.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 467737
|
| Accepted_Therapeutic_Use_For | Treatment of acute symptomatic deep venous thrombosis (DVT) with or without a pulmonary embolism (PE), in conjunction with warfarin.
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0354599
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |